Tuesday Jul 8
Halozyme Attracting Attention With Upcoming Adcom And Potential...
Halozyme and Baxter Pharma have a Food and Drug Administration Advisory Committee meeting coming up on July 31. The adcom will give guidance on whether Halozyme's Biologics License Application for its Human Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase is acceptable in its new amended form.
On the Move: Big personnel changes in local biotech industry
Here's a summary of recent personnel changes and board appointments announced at Massachusetts biotech, pharmaceutical and medical device companies: Voyager Therapeutics, a gene therapy company in Cambridge developing treatments for diseases of the central nervous system, has named Robert G. Pietrusko as senior vice president of regulatory affairs.
Spark Therapeutics Appoints Industry Leaders And To Board Of Directors
We are thrilled that such talented and respected biopharmaceutical industry leaders are joining our mission to deliver one-time, curative therapies to address severe rare diseases," said , co-founder and CEO.